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The past decade has seen a significant 
increase in the amount of funds avail-
able for international health activities. 
This is due largely to the generosity of 
private foundations, particularly the 
Bill & Melinda Gates Foundation, and 
some bilateral donors. Although this 
increase in support has already made 
a significant impact on the health of 
peoples in developing countries, the 
allocation of funds for disease-specific 
activities has become unbalanced, with 
some areas receiving generous support 
and others almost none. The most dra-
matic example of this is shown by the 
resources made available to fight AIDS, 
tuberculosis and malaria – the so-called 
“big three” – and those devoted to the 
two main killers of children, pneumo-
nia and diarrhoeal disease.
Pneumonia, the world’s most 
important cause of child death,1 has 
attracted remarkably little attention over 
the past decade. There has been very 
little research on the disease, apart from 
trials of pneumococcal and Haemophilus 
influenzae type b (Hib) vaccines, which 
included evaluations of the impact on 
these vaccines on pneumonia,2–5 and 
some studies on the case management 
of pneumonia.6–9 Country-level efforts 
to prevent pneumonia mortality have 
been limited to case management, par-
ticularly the Integrated Management 
of Childhood Illness (IMCI) strategy, 
which incorporates standardized case 
management of suspected pneumo-
nia cases.10 A recent analysis of donor 
spending on maternal and child health 
in developing countries showed that 
barely 1% was allocated to IMCI.11 In 
contrast, new pneumococcal conjugate 
vaccines, whose life-saving potential is 
probably similar to that of IMCI, have 
attracted a great deal of attention, with 
large sums of money being allocated to 
support early use of these vaccines by 
the GAVI Alliance and through innova-
tive funding mechanisms such as the 
Advanced Market Commitment (AMC) 
and the International Finance Facility 
for Immunization (IFFIm).
In 2006, there was a substantial 
increase in international awareness 
about pneumonia, helped by the 
publication of a report by the United 
Nations Children’s Fund (UNICEF) 
and WHO.12 There are promising signs 
that this awareness will lead to increased 
funding for both control programmes 
and research activities. When new funds 
become available in a particular field, it 
is not uncommon to see special interest 
groups competing for them, claiming 
that their strategy or product is superior 
to others and should therefore receive 
most of the new resources.
However, there are encouraging 
signs that this will not happen with 
childhood pneumonia. In March 2007, 
WHO and UNICEF convened a 
meeting in Geneva to establish a Global 
Action Plan for Pneumonia (GAPP). 
The meeting was attended by experts 
in the four areas that offer the best 
prospects for pneumonia control – case 
management (IMCI), vaccination (Hib 
and pneumococcal), environmental 
health (reduced indoor air pollution) 
and nutrition. The group unanimously 
concluded that attention to all of these 
areas will be needed to control the 
global problem of childhood pneumo-
nia, and urged that the global response 
to pneumonia mortality be balanced 
and equitable. As an initial step, group 
members will prepare a series of review 
papers summarizing the evidence that 
specific interventions will lead to reduc-
tions in pneumonia incidence and/or 
pneumonia mortality. These papers 
will be accompanied by analyses of the 
comparative or additive impact of these 
interventions in different settings and 
an analysis of their potential to reduce 
inequity in child health and mortality. 
In Spring 2008, the Bulletin will pub-
lish shortened versions of some of these 
papers in a theme issue on childhood 
pneumonia prevention and control.
To complement these 
commissioned papers, the Bulletin 
welcomes submissions of papers 
on childhood pneumonia for this 
theme issue. We are particularly 
interested in Research, Lessons from 
the field or Perspectives dealing 
with epidemiology of pneumonia, 
improved methods for the diagnosis of 
pneumonia, etiology of pneumonia, 
the impact on pneumonia mortality 
of case management, vaccines, and 
environmental and nutritional 
interventions.
Manuscripts should be submitted 
to http://submit.bwho.org by 1 October 
2007, respecting the Guidelines for 
Contributors and accompanied by a 
cover letter mentioning this call for 
papers.  O
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